Listen to a rapid review of the key hepatology studies from Boston 2016 expected to affect clinical practice, followed by expert answers to participants’ questions.
In this Expert Analysis, Ira M. Jacobson, MD, and Stefan Zeuzem, MD, provide expert interpretation of the most clinically important new data on HCV, HBV, and NASH from this important annual conference.
In this downloadable slideset, expert faculty members Ira M. Jacobson, MD, and Stefan Zeuzem, MD, summarize key studies from this important annual conference.
The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.
The treatment of NASH has challenges not seen in patients with HCV infection, but new trends are emerging.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.